Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25


Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.

Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, Hoon DS.

Ann Surg. 2006 Nov;244(5):799-804.


Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci.

Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, Jang HC, Park SH, Park DJ, Cho BY.

Cancer. 2006 Oct 15;107(8):1831-8.


The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2006 Sep;65(3):364-8.


Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.

Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA.

Cancer Res. 2006 Jul 1;66(13):6521-9.


B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.

Trovisco V, Soares P, Sobrinho-Simões M.

Hum Pathol. 2006 Jul;37(7):781-6. Review.


Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.

Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M.

J Clin Endocrinol Metab. 2006 Sep;91(9):3667-70. Epub 2006 Jun 13.


Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.

Endocr Relat Cancer. 2006 Jun;13(2):455-64.


Increasing incidence of thyroid cancer in the United States, 1973-2002.

Davies L, Welch HG.

JAMA. 2006 May 10;295(18):2164-7.


The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.

Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2005 Nov;63(5):588-93.


No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT.

Clin Endocrinol (Oxf). 2005 Oct;63(4):461-6.


BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW.

J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9. Epub 2005 Sep 20.


BRAF mutation in thyroid cancer.

Xing M.

Endocr Relat Cancer. 2005 Jun;12(2):245-62. Review.


Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma.

Shattuck TM, Westra WH, Ladenson PW, Arnold A.

N Engl J Med. 2005 Jun 9;352(23):2406-12. Erratum in: N Engl J Med. 2005 Oct 13;353(15):1640.


Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.

Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M.

Virchows Arch. 2005 Jun;446(6):589-95. Epub 2005 May 19.


Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA.

Cancer Res. 2005 May 15;65(10):4238-45.


The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma.

Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, Lushnikov E, Kumagai A, Nakashima M, Meirmanov S, Mine M, Hayashi T, Yamashita S.

Int J Oncol. 2004 Dec;25(6):1729-35.


BRAF mutations in an Italian cohort of thyroid cancers.

Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P.

Clin Endocrinol (Oxf). 2004 Aug;61(2):239-43.


Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival.

Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK.

Cancer. 2004 Jul 1;101(1):3-27.


BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.

Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH.

Mod Pathol. 2004 Nov;17(11):1359-63.


BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.

Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F.

J Clin Endocrinol Metab. 2004 May;89(5):2414-20.


Supplemental Content

Support Center